BR9812492A - Composto, uso do mesmo, formulação farmacêutica, e, processos para o tratamento de uma doença cardiovascular, para o tratamento de uma vasoconstrição, e para a preparação de compostos - Google Patents

Composto, uso do mesmo, formulação farmacêutica, e, processos para o tratamento de uma doença cardiovascular, para o tratamento de uma vasoconstrição, e para a preparação de compostos

Info

Publication number
BR9812492A
BR9812492A BR9812492-7A BR9812492A BR9812492A BR 9812492 A BR9812492 A BR 9812492A BR 9812492 A BR9812492 A BR 9812492A BR 9812492 A BR9812492 A BR 9812492A
Authority
BR
Brazil
Prior art keywords
treatment
vasoconstriction
compounds
processes
compound
Prior art date
Application number
BR9812492-7A
Other languages
English (en)
Inventor
Thomas D Ambra
Nils-Ake Bergman
Garry Pilling
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of BR9812492A publication Critical patent/BR9812492A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
    • C07C279/14—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by carboxyl groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Abstract

"COMPOSTO, USO DO MESMO, FORMULAçãO FARMACêUTICA, E, PROCESSOS PARA O TRATAMENTO DE UMA DOENçA CARDIOVASCULAR, PARA O TRATAMENTO DE UMA VASOCONSTRIçãO, E PARA A PREPARAçãO DE COMPOSTOS". Proporciona-se compostos farmaceuticamente úteis de fórmula (I) em que Ar¹, R¹, R², R³, R^ 4^, R^ 5^ e R^ 6^ têm significados dados na descrição, que são úteis como antagonistas do neuropeptídeo Y e, em particular, no tratamento de doenças cardiovasculares, por exemplo, vasoconstrição.
BR9812492-7A 1997-09-23 1998-09-21 Composto, uso do mesmo, formulação farmacêutica, e, processos para o tratamento de uma doença cardiovascular, para o tratamento de uma vasoconstrição, e para a preparação de compostos BR9812492A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9703414A SE9703414D0 (sv) 1997-09-23 1997-09-23 New compounds
PCT/SE1998/001686 WO1999015498A1 (en) 1997-09-23 1998-09-21 New npy antagonists

Publications (1)

Publication Number Publication Date
BR9812492A true BR9812492A (pt) 2000-09-26

Family

ID=20408331

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9812492-7A BR9812492A (pt) 1997-09-23 1998-09-21 Composto, uso do mesmo, formulação farmacêutica, e, processos para o tratamento de uma doença cardiovascular, para o tratamento de uma vasoconstrição, e para a preparação de compostos

Country Status (21)

Country Link
US (1) US6127414A (pt)
EP (1) EP1017672B1 (pt)
JP (1) JP2001517651A (pt)
KR (1) KR20010024220A (pt)
CN (1) CN1279666A (pt)
AR (1) AR017138A1 (pt)
AT (1) ATE228500T1 (pt)
AU (1) AU9288998A (pt)
BR (1) BR9812492A (pt)
CA (1) CA2303528A1 (pt)
DE (1) DE69809782T2 (pt)
EE (1) EE200000171A (pt)
IL (1) IL134993A0 (pt)
IS (1) IS5410A (pt)
NO (1) NO20001483L (pt)
PL (1) PL339617A1 (pt)
SE (1) SE9703414D0 (pt)
SK (1) SK3602000A3 (pt)
TR (1) TR200000785T2 (pt)
WO (1) WO1999015498A1 (pt)
ZA (1) ZA988353B (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9802075D0 (sv) * 1998-06-11 1998-06-11 Astra Ab New use
US6312898B1 (en) * 1999-04-15 2001-11-06 Hormos Medical Oy, Ltd. Diagnosis of a person's risk of developing atherosclerosis or diabetic retinopathy based on leucine 7 to proline 7 polymorphism in the prepro-neuropeptide Y gene
SE9902596D0 (sv) * 1999-07-06 1999-07-06 Astra Ab Pharmaceutically active compounds
EP1095933A1 (en) 1999-10-30 2001-05-02 Aventis Pharma Deutschland GmbH Novel N-guanidinoalkylamides, their preparation, their use, and pharmaceutical preparations comprising them
SE0101328D0 (sv) * 2001-04-12 2001-04-12 Astrazeneca Ab Therapeutic treatment
JP4010951B2 (ja) * 2001-05-15 2007-11-21 大正製薬株式会社 アルギニン誘導体
WO2004098591A2 (en) 2003-05-05 2004-11-18 Probiodrug Ag Inhibitors of glutaminyl cyclase and their use in the treatment of neurological diseases
EP1680120A2 (en) 2003-11-03 2006-07-19 Probiodrug AG Combinations useful for the treatment of neuronal disorders
FR2864830B1 (fr) * 2004-01-06 2006-03-10 Centre Nat Rech Scient Procede de synthese sur support solide de composes peptidiques, notamment de composes peptidiques comportant un residu arginine
CN1918131B (zh) 2004-02-05 2011-05-04 前体生物药物股份公司 谷氨酰胺酰基环化酶抑制剂
FR2884516B1 (fr) * 2005-04-15 2007-06-22 Cerep Sa Antagonistes npy, preparation et utilisations
KR100689499B1 (ko) * 2005-10-26 2007-03-02 삼성전자주식회사 휴대단말기에서 키 설정 정보 디스플레이 방법
WO2007064272A1 (en) * 2005-11-29 2007-06-07 Astrazeneca Ab Benzhydryl amide derivatives as cannabinoid receptor antagonists or inverse agonists
WO2008055945A1 (en) 2006-11-09 2008-05-15 Probiodrug Ag 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
SI2091948T1 (sl) 2006-11-30 2012-07-31 Probiodrug Ag Novi inhibitorji glutaminil ciklaze
EP2481408A3 (en) 2007-03-01 2013-01-09 Probiodrug AG New use of glutaminyl cyclase inhibitors
DK2142514T3 (da) 2007-04-18 2015-03-23 Probiodrug Ag Thioureaderivater som glutaminylcyclase-inhibitorer
AU2010294214B2 (en) 2009-09-11 2015-05-07 Vivoryon Therapeutics N.V. Heterocylcic derivatives as inhibitors of glutaminyl cyclase
JP6026284B2 (ja) 2010-03-03 2016-11-16 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤
AU2011226074B2 (en) 2010-03-10 2015-01-22 Vivoryon Therapeutics N.V. Heterocyclic inhibitors of glutaminyl cyclase (QC, EC 2.3.2.5)
EP2560953B1 (en) 2010-04-21 2016-01-06 Probiodrug AG Inhibitors of glutaminyl cyclase
JP6050264B2 (ja) 2011-03-16 2016-12-21 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤としてのベンゾイミダゾール誘導体
PL3461819T3 (pl) 2017-09-29 2020-11-30 Probiodrug Ag Inhibitory cyklazy glutaminylowej

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5873821A (en) * 1992-05-18 1999-02-23 Non-Invasive Technology, Inc. Lateralization spectrophotometer
DE4326465A1 (de) * 1993-01-20 1995-02-09 Thomae Gmbh Dr K Aminosäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
DE19544686A1 (de) * 1995-11-30 1997-06-05 Thomae Gmbh Dr K Aminosäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
DE19544687A1 (de) * 1995-11-30 1997-06-05 Thomae Gmbh Dr K Aminosäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
CA2242579A1 (en) * 1996-01-09 1997-07-17 Eli Lilly And Company Benzimidzolyl neuropeptide y receptor antagonists
DE69724941T2 (de) * 1996-03-21 2004-07-15 Banyu Pharmaceutical Co., Ltd. Aminopyridin-derivate
WO1997046250A1 (en) * 1996-06-04 1997-12-11 Synaptic Pharmaceutical Corporation Methods of modifying feeding behavior, compounds useful in such methods, and dna encoding a hypothalamic atypical neuropeptide y/peptide yy receptor (y5)
ATE230403T1 (de) * 1996-07-23 2003-01-15 Neurogen Corp Einige amido- und ammo- substituierte benzylaminderivate: eine neue klasse von neuropeptid y1 spezifische ligande
CA2260982A1 (en) * 1996-07-23 1998-01-29 Neurogen Corporation Certain substituted benzylamine derivatives; a new class of neuropeptide-y1 specific ligands
ATE239002T1 (de) * 1996-07-23 2003-05-15 Neurogen Corp Einige amido-und amino-substituierte benzylaminderivate: eine neue klasse von neuropeptid y1 spezifischen liganden
DE69713402T2 (de) * 1996-08-23 2002-11-07 Agouron Pharma Liganden des neuropeptids y
EP0955293B1 (en) * 1996-12-03 2003-03-19 Banyu Pharmaceutical Co., Ltd. Urea derivatives
WO1998025907A1 (fr) * 1996-12-12 1998-06-18 Banyu Pharmaceutical Co., Ltd. Derives de pyrazole
US6166038A (en) * 1996-12-13 2000-12-26 Banyu Pharmaceutical Co., Ltd. Aminopyrazole derivatives
CA2274594C (en) * 1996-12-16 2006-10-10 Banyu Pharmaceutical Co., Ltd. Aminopyrazole derivatives
EP0986553A4 (en) * 1997-02-04 2000-12-27 Bristol Myers Squibb Co DIHYDROPYRIMIDONE DERIVATIVES AS NPY ANTAGONISTS
EP0927166A1 (en) * 1997-02-14 1999-07-07 Bayer Corporation Amides as npy5 receptor antagonists
JP2002241368A (ja) * 1997-02-18 2002-08-28 Shionogi & Co Ltd 新規ベンゾラクタム誘導体およびそれを含有する医薬組成物
WO1998040356A1 (fr) * 1997-03-12 1998-09-17 Banyu Pharmaceutical Co., Ltd. Medicaments contenant des derives d'aminopyridine comme ingredient actif
US5889016A (en) * 1997-06-26 1999-03-30 Bristol-Myers Squibb Company Dihydropyrimidone derivatives as NPY antagonists

Also Published As

Publication number Publication date
WO1999015498A1 (en) 1999-04-01
DE69809782T2 (de) 2003-07-17
US6127414A (en) 2000-10-03
PL339617A1 (en) 2001-01-02
KR20010024220A (ko) 2001-03-26
AR017138A1 (es) 2001-08-22
IL134993A0 (en) 2001-05-20
DE69809782D1 (de) 2003-01-09
CA2303528A1 (en) 1999-04-01
IS5410A (is) 2000-03-20
ZA988353B (en) 1999-03-23
EP1017672B1 (en) 2002-11-27
SK3602000A3 (en) 2001-01-18
TR200000785T2 (tr) 2000-09-21
NO20001483L (no) 2000-05-23
JP2001517651A (ja) 2001-10-09
NO20001483D0 (no) 2000-03-22
EP1017672A1 (en) 2000-07-12
ATE228500T1 (de) 2002-12-15
EE200000171A (et) 2001-04-16
SE9703414D0 (sv) 1997-09-23
AU9288998A (en) 1999-04-12
CN1279666A (zh) 2001-01-10

Similar Documents

Publication Publication Date Title
BR9812492A (pt) Composto, uso do mesmo, formulação farmacêutica, e, processos para o tratamento de uma doença cardiovascular, para o tratamento de uma vasoconstrição, e para a preparação de compostos
BR9911488A (pt) Composto, uso do mesmo, composição farmacêutica, e, processos para tratamento ou de profilaxia de doenças inflamatórias, e para a preparação de um composto
BR9714082A (pt) Composto, uso do mesmo, composição farmacêutica, e, processos para tratamento ou profilaxia de doenças inflamatórias, e para a preparação de um composto.
BR9911482A (pt) Composto, composição farmacêutica, uso do composto, e, processos para o tratamento ou profilaxia de doenças inflamatórias, e para a preparação de um composto
BR0007500A (pt) Composto triazol, fármaco, e, uso do composto
BR9909565A (pt) Derivados bicìclicos do ácido hidroxâmico
BR9811022A (pt) Composto, composição farmacêutica, e, processo para preparação de um composto
TR200302214T4 (tr) Psoriasis tedavisi için kullanilan pteridine bileşkenleri
PT896533E (pt) Pentafluorobenzenosulfonamidas e analogos
BR0015605A (pt) Composição e uso
BRPI0215312B8 (pt) composto, uso de um composto, composição farmacêutica, e processo para a preparação de um composto
PT1003504E (pt) Compostos quimicos
BR9916282A (pt) Composto, uso de um um composto e método de tratamento
BR9910583A (pt) Aminotetralinas n-substituìdas como ligantes para o receptor de neuropeptìdeo y y5 úteis no tratamento de obesidade e outros distúrbios
ATE215954T1 (de) Pyrazolo(4,3-d)pyrimidin-derivate und diese enthaltende pharmazeutische zubereitungen
BR0111667A (pt) Novos compostos
BR0210122A (pt) Composto ou um sal farmaceuticamente aceitável do mesmo, método para o tratamento ou prevenção de uma doença, uso do composto ou de seu sal, e, método para preparar o mesmo
ATE242783T1 (de) Glycopeptid-derivate und pharmazeutische zusammensetzungen, die sie enthalten
BR9907270A (pt) Composto, composição farmacêutica, uso de um composto, e, processos para tratamento ou profilaxia de doenças inflamatórias, por exemplo, asma ou copd, e para a preparação de um composto
ES2191048T3 (es) Derivados de oxazolidinona y compuestos farmaceuticos que los contienen.
CL2009001279A1 (es) Compuestos derivados de nociceptina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del dolor (sol. divisional 2103-03).
AR026064A1 (es) Compuestos de oxabispidina, formulacion farmaceutica, uso de estos compuestos para la manufactura de medicamentos, proceso para la preparacion de estos compuestos, e intermediarios.
PT1222195E (pt) Novos compostos de tiazolo(4,5-d)pirimidina
BR9811028A (pt) Composto, composição farmacêutica, e, processos de tratamento de uma doença de agregação de plaquetas e para a preparação de um composto
FI920023A0 (fi) Heteroarylpiperazinfoereningar som antipsykotiska aemnen.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 4A,5A,6A,7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1890 DE 27/03/2007.